It is this collaborative process in research and product development together with venture funding that allows OmegaGenesis to greatly advance the treatment of primary diseases potentially affecting hundreds of millions globally.
OmegaGenesis through its collaboration with Mayo Clinic has retained exclusive license to further test Angiogenesis characteristics of these nano rods and develop products. The agreement includes existing intellectual property and a commitment to ongoing collaborative research projects in early-development stages at Mayo Clinic.
In addition to licensing technology and patents to OmegaGenesis, Mayo Clinic and OmegaGenesis scientists will cooperate in conducting lab tests.
OmegaGenesis, Inc. is a venture funded bio-technology company based in Gilroy, California and Rochester, Minnesota. OmegaGenesis was founded in 2008 to bring Mayo Clinic core research and resulting products to market based on the idea that controlling blood vessel growth would improve human body management for a diverse set of medical applications ranging from cancer and malignancies treatments to common wound healing and tissue reactivation.
The Company was founded to discover and produce suitable nano-materials to manage human body functions at a nano scale -- the cell and sub-cell level -- accelerating cellular-based biologic therapies to control blood vessel growth. These nano-materials will enable doctors to treat disease at sub-cell level in a non-intrusive manner instead of treating the disease at the organ or tissue level.
Our mission emphasizes collaborative research in partnership with leading medical centers, rapid product design, development, and validation. OmegaGenesis collaborates with strategic academic and corpor
Copyright©2008 PR Newswire.
All rights reserved